Evidence map›Paper›PMID 29423406›Full record

ReviewBioMed research international2017

Clinicopathological Characteristics, Treatment, and Prognosis of Rarely Primary Epididymal Adenocarcinoma: A Review and Update.

Zi-Jun Zou, Ying-Ming Xiao, Zhi-Hong Liu, Ruo-Chen Zhang, Jia-Yu Liang, Yong-Quan Tang, Yi-Ping Lu

Abstract readReview
In one paragraph

Review in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zi-Jun ZouInstitute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Ying-Ming XiaoDepartment of Urology, Sichuan Cancer Hospital & Institute, Chengdu, Sichuan 610041, China.
Zhi-Hong LiuInstitute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.ORCID 0000-0002-2857-5231
Ruo-Chen ZhangDepartment of Urology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China.
Jia-Yu LiangInstitute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Yong-Quan TangInstitute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Yi-Ping LuInstitute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary epididymal adenocarcinoma (PEA) is exceedingly rare. Only 22 cases had been published worldwide by 2008; nearly 80% of these cases were reported before 2007. In order to investigate the current clinical status of PEA, we search for relevant literatures with "epididymis and adenocarcinoma" and "epididymal and adenocarcinoma" as keywords published between January 1997 and November 2017 in PubMed. As a result, 17 cases are identified. We review these cases and summarize new and important perspectives about the clinicopathological characteristics, diagnosis, treatment, and prognosis of PEA in the present review.

Indexed as

AdenocarcinomaEpididymisHumansMalePrognosisTesticular Neoplasms

Identifiers

PMID29423406
PMCPMC5750466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.